Novartis AG (NOVN.SW)

Exchange: SIX Swiss Exchange
Currency: CHF

Price: 80.78 (Close)



52 Week range 200d Moving Avg. Beta
72.85 – 86.90 80.08 0.54
Dividend Dividend Yield Ex-Dividend date
3.10 3.84% 2022-03-08
P/E Ratio Latest EPS DGR 3 years
8.12 9.95 2.33%
Near Fair Value
Low Volatility
Dividend Growth


Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company’s Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company’s Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products; and biotechnology manufacturing services. The company’s Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; TRIO; Verily; and Pharming Group N.V. The company was founded in 1895 and is headquartered in Basel, Switzerland.


Sector: Industry:
Healthcare Drug Manufacturers – Major

Environment, Social and Governance (ESG) Ratings

Total ESG Score

20 – 20 percentile


3 – 0 percentile


6 – 0 percentile


7 – 0 percentile

Controversy level



see MSCI ESG rating explained

Dividend Safety Metrics

Latest EPS 9.95
Annual Payout 3.10
Payout Ratio 31.16%
Dividend growth 24 Years
Dividend Score 80
Dividend Coverage Ratio 3.21
Altman-Z score 0.00


Novartis AG (NOVN.SW) Valuation

Novartis AG’s current dividend yield of 3.84% is 9% just above its 5-year average. The 5-year average dividend yield is 3.51% (see red-line in chart). This indicates the stock looks reasonably valued today.

Novartis AG (NOVN.SW) Performance

The chart below displays the total price return(%) of Novartis AG for different periods:


Novartis AG (NOVN.SW) Total Return

The chart below displays the (CAGR) total return (%) including all dividends paid of Novartis AG for different periods:


Dividend Scorecard

Dividend Yield (TTM) Annual Payout Payout Ratio Dividend growth
3.84 3.10 31.16% 24 Years


Dividend Growth Summary

3 Year Growth Rate (CAGR) 2.33%
5 Year Growth Rate (CAGR) 2.13%
10 Year Growth Rate (CAGR) 3.15%

Dividend Growth Rates History

Year Payout Amount Annual Payout Growth (YoY)
2022 3.100 3.3%
2021 3.000 1.7%
2020 2.950 17.1%
2019 2.519 -10.0%
2018 2.800 1.8%
2017 2.750 1.9%
2016 2.700 3.8%
2015 2.600 6.1%
2014 2.450 6.5%
2013 2.300 2.2%
2012 2.250 2.3%
2011 2.200 4.8%
2010 2.100 5.0%
2009 2.000 25.0%
2008 1.600 18.5%

Novartis AG (NOVN.SW) Dividend Payment History